Welcome, fellow medical investor. I'm not quite sure what your points are other than that it is indeed difficult to develop a HSV-1 vaccine. The preclinical studies on mice were and are absolutely necessary before progressing Phase 1 trials on humans. As for the 'very small' sample sizes, 20-25 subjects is standard for Phase 1 and definitely statistically significant. So I really don't know why you brought up either points. But I do agree that if there is a robust immune response in Phase II trials, Professor Frazer has won the global research race to cure HSV-1. I reckon he's got this. :)
updated ballieu report - target range 25-55c, page-43
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.11 |
Change
-0.290(1.88%) |
Mkt cap ! $321.3M | |||
| Open | High | Low | Value | Volume |
| $15.15 | $15.39 | $15.01 | $54.11K | 3.573K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 298 | $15.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.35 | 583 | 3 |
View Market Depth
| Last trade - 12.51pm 22/08/2024 (20 minute delay) ? |
| AVR (ASX) Chart |